A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
Inclusion Criteria:
Exclusion Criteria:
CABA, Buenos Aires C1120AAC, Argentina
CABA, Ciudad Auton. de Buenos Aires C1018DES, Argentina
Ciudad Autón. de Buenos Aires, Ciudad Auton. de Buenos Aires C1425AGC, Argentina
Saint Stefan, Styria 8511, Austria
Bruxelles - Brussel, 1070, Belgium
Smith Falls, Ontario K7A 4W8, Canada
Monza Brianza, Lombardy 20832, Italy
Nakagami-gun, Okinawa 901-2393, Japan
Shibuya-ku, Tokyo 150-0002, Japan
Tacchikawa, Tokyo 190-8531, Japan
Kelantan, 15200, Malaysia
Kelantan, Malaysia
México D.F., Mexico City 14080, Mexico
Puerto de Veracruz, Veracruz 91900, Mexico
Hawkes Bay, 4130, New Zealand
Lenasia South, Gauteng 1835, South Africa